PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.860
- +0.030+1.64%
Close Feb 14 16:00 ET
- 1.802
- -0.058-3.13%
Post 17:36 ET
92.64MMarket Cap-0.60P/E (TTM)
1.880High1.810Low119.81KVolume1.840Open1.830Pre Close221.46KTurnover0.39%Turnover RatioLossP/E (Static)49.81MShares20.22052wk High0.50P/B57.08MFloat Cap1.55052wk Low--Dividend TTM30.69MShs Float24.420Historical High--Div YieldTTM3.83%Amplitude1.550Historical Low1.848Avg Price1Lot Size
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025
HilleVax Stock Forum
📊⚡️📊
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
No comment yet